Sirius Therapeutics Secures $50M for siRNA Cardiometabolic Therapy Development

Sirius Therapeutics, a biotechnology enterprise based in San Diego and Shanghai, recently announced the completion of a significant financial milestone. The company has successfully secured nearly $50 million in Series B2 funding, a move poised to propel the clinical development of its groundbreaking small interfering RNA (siRNA) therapeutics targeted at cardiometabolic disorders. This round of financing was spearheaded by a prominent corporate venture capital firm and saw participation from a new stakeholder, BioTrack Capital, alongside existing backers such as OrbiMed, Creacion Ventures, and Hankang Capital.

Commenting on this achievement, Dr. Qunsheng Ji, CEO of Sirius Therapeutics, emphasized that this financial milestone is a substantial validation of the company’s achievements and future strategy. Dr. Ji expressed gratitude towards the investors, both new and existing, for their unwavering support. The newly acquired funds are earmarked to further the company’s clinical pursuits and broaden its therapeutic offerings, aimed at delivering transformative siRNA treatments to patients suffering from chronic illnesses globally.

Sirius Therapeutics is advancing three clinical-stage programs and possesses a robust preclinical pipeline. The leading candidate, SRSD107, is a cutting-edge, long-acting anticoagulant designed for thromboembolic disorders. This compound is on the cusp of Phase 2 clinical development in Europe, with an application recently submitted to the European Medicines Agency (EMA) to commence a Phase II trial. Additionally, the company is making strides with SRSD216, a novel siRNA therapeutic for hyperlipoproteinemia, which has received regulatory approvals from both the U.S. FDA and the China National Medical Products Administration (NMPA). Phase 1 studies for SRSD216 are already underway for patients with atherosclerotic cardiovascular disease. Moreover, SRSD101, aimed at treating dyslipidemia, is currently undergoing Phase 1 clinical trials in China.

Founded in 2021, Sirius Therapeutics is dedicated to developing transformative siRNA therapies for individuals with chronic diseases across the globe. The company has established an innovation hub in the United States, along with a translational medicine center in China, to spearhead state-of-the-art solutions for managing and treating chronic conditions. To date, Sirius has successfully raised close to $150 million to support its ambitious endeavors.